An evolving role for oral fluoropyrimidine drugs.
Diasio
Robert B
RB
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D004358:Drug Therapy / Q000639:trends; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D014498:Uracil / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D011743:Pyrimidines; D003841:Deoxycytidine; C073482:eniluracil; D014498:Uracil; D000069287:Capecitabine; D005472:Fluorouracil